Vascular Medicine: Recent Episodes
ReachMD
Host: Manesh R. Patel, MD
Host: M. Cecilia Bahit, MD
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Manesh R. Patel, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: M. Cecilia Bahit, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Christopher B. Granger, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Deborah Siegal, MD, MSc, FRCPC
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Craig I. Coleman, PharmD, FASHP
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Craig I. Coleman, PharmD, FASHP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Craig I. Coleman, PharmD, FASHP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Jan Beyer-Westendorf, MD, PhD
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Host: Suzanne J. Baron, MD
Guest: Jonathan A. Bradlow, MD, FACC
Guest: Kendra J. Grubb, MD
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sean Lau, RN, VA-BC
What are some ways we can reduce the prevalence of difficult venous access? Dr. Charles Turck is joined by Sean Lau, a vascular access specialist at Stanford Health Care, to share strategies to help reduce DIVA rates and improve vascular access care.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Matt Birnholz, MD
Guest: Kelly Cawcutt, MD
Adapting to the drastic changes COVID-19 has forced clinicians to make is one of the many obstacles faced during this pandemic. Joining Dr. Matt Birnholz to talk about how vascular access teams are changing their protocols and roles in response to COVID-19 is Dr. Kelly Cawcutt, an infectious disease and critical care physician at the University of Nebraska Medical Center.
Published May 5, 2020
Guest: Brett Nowlan, MD
Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William W. Li, MD
As the number of new COVID-19 infections continues to decrease and the United States begins to open back up, it’s important to note that there are patients who have survived COVID-19 but are still suffering. The newly coined term “COVID long-haulers” refers to those patients who continue to have symptoms even after the acute infection is resolved. Joining Dr. Andrew Wilner to share what we know so far about COVID long-haulers and how we can help them is vascular biologist Dr. William Li.
Host: Paul Doghramji, MD
Guest: Nadine Nakazawa, RN, BS
How does the patient-centric experience model for vascular access care differ from what we're used to doing, and what does it actually look like in practice? Joining Dr. Paul Doghramji to share what we need to know about the development and goals of patient-centered vascular access care is Ms. Nadine Nakazawa, a vascular access nurse specialist at Stanford Health Care.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam Olsen, MS, PA-C
Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.
Host: Jennifer Caudle, DO
Guest: Kelly Cawcutt, MD
How has the COVID-19 pandemic changed vascular access paradigms in the intensive care unit? Joining Dr. Jennifer Caudle to share her story and lessons learned from the pandemic is Dr. Kelly Cawcutt, an Assistant Professor in the Department of Internal Medicine and the Associate Medical Director of Infection Control and Epidemiology at the University of Nebraska Medical Center.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
With no standard criteria available, how do we detect broken heart syndrome in our patients? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, shares what we should be looking for.
Host: Hector O. Chapa, MD, FACOG
Guest: Andrew Little, DO
When vascular access is compromised, intraosseous access, or IO access, can help prevent fatal consequences. What do we need to know about implementing and managing this type of device? Dr. Hector Chapa is joined by Dr. Andy Little, the Associate Program Director for AdventHealth Orlando Emergency Medicine Residency, to share some insight on IO vascular access.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Salim S. Virani, MD, PhD, FACC, FAHA, FASPC
What is the leading cause of death worldwide? Dr. Matthew Sorrentino sits down with Dr. Salim Virani, who's a professor of medicine at Baylor College of Medicine in Houston, Texas, and the Cardiovascular Disease Fellowship director at Baylor, to discuss how the COVID-19 pandemic has impacted cardiovascular disease globally.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Orlando Chirikian
A recent study revealed that our heart cells undergo changes in space, but what can that tell us about our heart health on Earth? Dr. Matt Sorrentino dives into the Cardinal Heart Study with Orlando Chirikian, a research scientist at the University of California, Santa Barbara.
Guest: Satish R. Raj, MD, MSCI
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 In these patients, there is insufficient compensatory peripheral release of norepinephrine, the major neurotransmitter responsible for blood pressure maintenance, upon standing or following postural change.2-4 Due to this norepinephrine deficiency, there is inadequate vasoconstriction to maintain blood pressure or cerebral blood flow.1,5 This may lead to symptoms of nOH which may increase the risk of falls and lead to serious consequences.2,3,6
Here. Dr. Satish Raj, Professor of Cardiac Sciences at the Libin Cardiovascular Institute at the University of Calgary's Cumming School of Medicine and Medical Director of Calgary Autonomic Clinic, discusses the pathogenesis of nOH, as well as the mechanisms behind therapeutic approaches to controlling its effects.
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011:21(2) 69-72.
- Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009:119(1):139-146.
- Freeman …
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: C. Michael Gibson, MD, FSCAI
Following a major cardiovascular event, what interventional strategies should we be considering? Dr. Matthew Sorrentino joins Dr. Michael Gibson, a professor of medicine and cardiology at the Beth Israel Deaconess Medical Center at Harvard Medical School in Boston, Massachusetts to discuss antiplatelet and anticoagulation strategies for patients with cardiovascular disease.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Eliot Brinton, MD, FAHA, FNLA
What do we need to know about the impact of triglyceride levels? Dr. Elliot Brinton, President at the Utah Lipid Center in Salt Lake City briefly dives into the impact that triglycerides have on our endothelial cells and LDL cholesterol.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
With an explosion in new medications to treat diabetes, Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss the cardiovascular risk benefits of these new diabetes treatments and how cardiologists can improve patient care.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Eliot Brinton, MD, FAHA, FNLA
One of the leading causes of death in the US, cardiovascular disease risk-reduction has neglected triglycerides. To explain why that is, Dr. Matthew Sorrentino discusses approaches to take when reducing the risk of cardiovascular disease with expert guest, Dr. Elliot Brinton, president of the Utah Lipid Center in Salt Lake City.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Arun Sharma, PhD
Can low gravity and space flight impact our cardiac function? Dr. Arun Sharma, a stem cell biologist at Cedars-Sinai Medical Center in California, joins Dr. Alan Brown to discuss the impact of outer space on the heart.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
The development of statin medications has pushed preventative treatment to the forefront of cardiology. How have advancements in prevention impacted the field? Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss prevention in cardiovascular disease and how cardiologist treat their patients.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Dr. Matthew Sorrentino sits down with Dr. Erin Michos, an Associate Professor of Medicine and the Director of Women’s Cardiovascular Health and the Associate Director of Preventive Cardiology at Johns Hopkins Medicine to discuss the ACC/AHA cholesterol guidelines, originally released in 2013 and updated in 2018.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Heval M. Kelli, MD
Dr. Matthew Sorrentino sits down with Dr. Heval Kelli, a cardiologist who specializes in general non-invasive cardiology and preventive cardiology at Northside Hospital, to discuss his recent nomination for ReachMD’s Heroes in Healthcare Initiative, honoring those recognized by their peers for outstanding contributions to medical care.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Nanette K. Wenger, MD, MACC, MACP, FAHA
Previously thought to mostly affect men, heart disease puts an equal or greater number of women at risk. What do we need to know about protecting them from this life-threatening condition? Dr. Nanette Wenger, a Professor of Medicine in the division of cardiology at Emory University School of Medicine, joins us to discuss the prevalence of heart disease among women.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host: Matthew Sorrentino, MD
Developments in the healthcare community have changed the field of preventative cardiology. But how have they impacted cardiology care? Heart Matters hosts Dr. Alan Brown and Dr. Mathew Sorrentino examine adherence to medicine, improvements to compliance, and new entries into the marketplace surrounding cardiology.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host: Matthew Sorrentino, MD
As the field of healthcare continues to change, how will the future of preventative cardiology be impacted? Join our Heart Matters hosts, Dr. Alan Brown and Dr. Mathew Sorrentino, as they sit down to discuss their experiences in preventative cardiology and the future of the healthcare system.
Host: Matthew Sorrentino, MD
Guest: Nosheen Reza, MD
While the field of cardiology has grown to become more inclusive, female-led research and diversity in study participants remain limited. How can we better understand this lack of representation? Tune in as Dr. Matthew Sorrentino explores a recent study on gender disparities in heart failure research with Dr. Nosheen Reza.
Host: Matthew Sorrentino, MD
Guest: Laetitia Guillemette, MSc, PhD
Heart disease is a leading cause of death in the United States and may impact young adults earlier than we think. Maybe even before they’re born. Joining Dr. Matthew Sorrentino is Dr. Laetitia Guillemette, who discusses her study published in the Canadian Medical Association Journal investigating the relationship between exposure to diabetes in the womb and heart disease in young adults and teenagers.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Daniel T. Lackland DrPH
For decades, news reports have focused on the prevalence of high blood pressure among adults in the U.S. But a recent study claims that blood pressure among these adults has actually decreased between 1960 and 2005. Here to divulge the surprising results of his study and discuss systolic blood pressure improvements in adults in the U.S. is Dr. Daniel Lackland.
Host: Matthew Sorrentino, MD
Guest: Jennifer N. Avari Silva, MD
Each year, more than 75 thousand cardiac ablation procedures are performed in the United States alone. Could something straight out of a science-fiction movie like holograms help improve physician accuracy and reduce the complications typically associated with this procedure? Talk a walk on the futuristic side of medicine with Dr. Matthew Sorrentino and Dr. Jennifer Silva, who co-led a team that tested a unique headset using mixed reality technology during cardiac ablation procedures at St. Louis Children’s Hospital.
Guest: Anil Agarwal, MD
How can healthcare professionals at the forefront of the pandemic protect the vascular integrity of COVID-19 patients undergoing acute dialysis procedures? Here to walk us through his process step by step is Dr. Anil Agarwal from the Ohio State University Wexner Medical Center.
Published August 19, 2020
Host: Matt Birnholz, MD
Guest: Anil Agarwal, MD
The emergence of blood clotting and clogged equipment for vascular procedures is a more recent—and troubling—phenomenon that’s emerged from the COVID-19 pandemic. Tune in as Dr. Anil Agarwal from the Ohio State University Wexner Medical Center discusses these two challenges and strategies for overcoming them.
Published August 13, 2020
Host: Matt Birnholz, MD
Guest: Wes Ely, MD, MPH
After surviving a critical illness, many patients look forward to their lives returning to normal, but unfortunately, that’s not always possible.
To uncover the far-reaching impacts of delirium, Dr. Matt Birnholz is joined by Dr. Wes Ely, Professor of Medicine and Co-Director of the Center for Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University’s School of Medicine which focuses on improving the lives and care of patients in the intensive care unit to ensure both physical and cognitive rehabilitation.
Host: Brian P. McDonough, MD, FAAFP
At the age of 35, Jessica Cross was pursuing a rewarding career and raising a family with her loving husband when she was dealt a crippling blow: suffering a stroke that left her paralyzed on the right side of her body and hospitalized for months.
Two years later, still in rehabilitation, Cross began punching at a keyboard to restore function in her arm and hand. Having little interest in typing mindlessly, this daily rehab exercise soon grew into writing what would become the book, Crossed Lines: What Lies Buried Within the Heart.
Host Dr. Brian McDonough sits down with Jessica Cross to talk about her journey through enduring this stroke, her recovery and rehab, and subsequent activism around education and wellness for stroke survivors.
Jessica Cross is an author, speaker, and Executive Director of Strong Cross Foundation.
Host: Brian P. McDonough, MD, FAAFP
Guest: Annalisa Scimemi
Hemorrhagic strokes account for about 200,000 strokes per year. Of those who survive, about 66 percent suffer some permanent brain damage. Our guest, biophysicist Dr. Annalisa Scimemi, has been studying the receptors in the brain that may contribute to brain damage immediately after hemorrhagic stroke. Alongside host Dr. Brian McDonough, she will discuss how to lessen the effects of brain damage following a stroke.
Host: Barnett Mennen, MD
Guest: Grace Wang, MD, FACS
Unclogging patient arteries is a key step to preventing stroke in patients with arterial disease. Whether it be preventing the operative stage, or surgery itself, advances in treatment at Penn Medicine are seeking to lessen the effects of arterial disease.
Host Dr. Barry Mennen welcomes Dr. Grace Wang, vascular surgeon and Director of the Vascular Laboratory at the Hospital of the University of Pennsylvania. Dr. Wang highlights the importance of early detection in arterial disease, as well as the symptoms and risk factors of the disease. She will also discuss the current and upcoming surgical intervention options at Penn Medicine.
Host: Barnett Mennen, MD
Guest: Deepak Sudheendra, MD, FSIR, RPVI
Host Dr. Barry Mennen joins Dr. Deepak Sudheendra, Assistant Professor of Clinical Radiology & Surgery at the Hospital of the University Of Pennsylvania Perelman School Of Medicine. Dr. Sudheendra will explain the difference between acute, subacute, and chronic deep vein thrombosis (DVT) and their complications. He will also discuss the scope of post thrombotic syndrome (PTS) and why it is so important to treat quickly and effectively.
Host: Jennifer Caudle, DO
Guest: Timothy W.I. Clark, MD
Host Dr. Jennifer Caudle welcomes Dr. Timothy Clark, Associate Professor of Clinical Radiology and the Director of Interventional Radiology at Penn Presbyterian Medical Center. Dr. Clark will review the prevalence of peripheral arterial disease (PAD) in the U.S., the central risk factors, and how PAD is properly diagnosed and managed. He will also review advanced endovascular procedures for PAD and other therapies that make a difference in patient care and outcomes.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA
Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their discussion focuses on lipid management to reduce atherosclerotic cardiovascular disease (ASCVD) risk in elderly patient populations. Thhis interview was recorded live at the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Alan Brown welcomes Dr. Penny Kris-Etherton, Distinguished Professor of Nutrition at Penn State and Past President of NLA. Dr. Kris-Etherton reviews the current dietary recommendations for saturated fat for the population at large and for reducing LDL-C levels. The two discuss the evidence to support these dietary recommendations and optimal replacement nutrients for dietary saturated fatty acids (SFAs).
Host: Jennifer Caudle, DO
Guest: Yuli Kim, MD
Advancements in cardiac surgery and medical care for pediatric patients over the past decades have produced a sizeable population of adults living with congenital heart disease. These adults and their unique health care needs expose an emerging gap in expertise for the cardiology community, where training in congenital heart disease management has traditionally been the provence of pediatric subspecialists. How can these adult patients find cardiologists familiar with their particular anatomy and problems, and what special care strategies must cardiologists be familiar with to provide optimal care?
Dr. Jennifer Caudle will discuss the selective health care needs and personalized management strategies for adults with congenital heart disease with Dr. Yuli Kim, Medical Director of the Philadelphia Adult Congenital Heart Disease Center and Assistant Professor of Medicine & Pediatrics at the University of Pennsylvania and the Children's Hospital of Philadelphia.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough speaks with Dr. Philip E. Empey, PharmD, PhD, Assistant Professor of Pharmacy and Therapeutics at the University of Pittsburg School of Pharmacy. Their discussion centers on advancements in genetic testing to detect variances in response to anticoagulation therapies for patients undergoing vascular procedures such as stent placements.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in clinical drug trials to perspectives on past and present guideline recommendations.
Host: Jennifer Caudle, DO
Guest: Scott O. Trerotola, MD, FACR, FSIR
Is there a way to predict complex removal of inferior vena cava filters, and if so, what is the success rate? Dr. Scott Trerotola adresses these and other questions in details. Dr. Trerotola is Stanley Baum Professor at the Hospital of the University of Pennsylvania, Chief of Vascular and Interventional Radiology and Vice Chair for Quality of the Department of Radiology at the University Of Pennsylvania Medical Center.
Host: Jennifer Caudle, DO
Guest: Pavan Atluri, MD
What are the latest advances in minimally invasive & robotic operations? And, which patients are candidates for robotic procedures? Host Dr. Jennifer Caudle welcomes Dr. Pavan Atluri, Assistant Professor of Surgery; Director of the Cardiac Transplantation and Mechanical Circulatory Assist Program; and, Director of the Minimally Invasive and Robotic Cardiac Surgery Program in the Division of Cardiovascular Surgery at the University of Pennsylvania. Dr. Atluri will discuss the latest advancements at Penn Medicine where he and his colleagues have been working for several years to perfect the robotic, minimally invasive, mitral valve repair procedure.
And, don't forget to view some of the additional content below.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Allan Sniderman, MD
Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman, Edwards Professor of Cardiology at McGill University, to discuss why we should pay more attention to the causes, and less to the risks, of cardiovascular disease.
Supported by an Educational Grant from AstraZeneca.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Keith C. Ferdinand, MD
Host Dr. Alan Brown is joined by Dr. Keith C. Ferdinand, Professor at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Ferdinand reviews the etiologies, diagnostic challenges, and management considerations for selective cardiac health issues prevalent in African American populations, from hypertension to coronary arterial calcium plaques to lipid levels.
Supported by an Educational Grant from AstraZeneca.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Dr. Don Wilson, Endocrinologist at Cook Children's Health Care System, Fort Worth, Texas. Dr. Wilson will review dyslipidemia in children and adolescent patients. Key points of their discussion will cover the association between abnormal lipid levels in children and an increased lifetime risk of atherosclerotic CVD, as well as, the CVD risk factors present in children and how it tracks from childhood to adulthood.
Supported by an Educational Grant from AstraZeneca.
Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
In this session of Lipid Luminations, host Dr. Alan Brown welcomes Dr. Merle Myerson, founder and director of the Cardiovascular Disease Prevention Program, Lipid Clinic, Pre-Exercise Heart Screening Program, and Cardiology Section/Institute for Advanced Medicine (HIV) at Mount Sinai St. Luke's and Mount Sinai Roosevelt Hospitals. Dr. Myerson reviews the guidelines for prevention, diagnosis, and management of dyslipidemia in patients with HIV.
Host: Maurice Pickard, MD
Stress and other negative emotions contribute to about 25 percent of heart attacks. But recent cutting-edge research shows that positive emotions can cause a chemical change in your body that directly improves your overall cardiovascular health. Dr. Maurice Pickard welcomes Dr. Michael Miller to discuss his book, Heal Your Heart: The Positive Emotions Prescription to Prevent and Reverse Heart Disease. Dr. Miller is a Professor of Cardiovascular Medicine, Epidemiology, and Public Health at the University of Maryland School of Mediicne and is the Director of the Center of Preventive Cardiology.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Janet Wright, MD
Heart disease and stroke are two of the leading causes of death in the United States. The Department of Health and Human Services, with several key partners, launched the Million Hearts national public-private initiative. Million Hearts aims to prevent one million heart attacks and strokes over five years through behavioral changes and clinical interventions. Host Dr. Alan Brown welcomes Dr. Janet Wright, Executive Director of Million Hearts in Washington, DC.
Supported by an Educational Grant from AstraZeneca.
Host: Brian P. McDonough, MD, FAAFP
Stress has long been associated with cardiovascular risk, but few studies have connected stress with worsened recovery rates after heart attacks. Moreover, the recently published discovery that women with mental stress may suffer worse outcomes recovering from heart attacks than men under similar conditions raises more questions than answers. What are the possible mechanisms by which this gender disparity in outcomes may occur, and how can clinicians help mitigate this risk? Dr. Brian McDonough welcomes Dr. Nieca Goldberg, cardiologist and director of the Joan H. Tisch Center for Women's Health at NYU Langone Medical Center.
Host: Lee Freedman, MD
Host Dr. Lee Freedman is joined by Francis Marchlinski, MD, Director of Electrophysiology at the University of Pennsylvania Health System; and, the Director of Electrophysiology Laboratory, Hospital of the University of Pennsylvania. In this segment, Dr. Marchlinski discusses premature ventricular contractions (PVCs), when to consider catheter ablation, the use of catheter ablation as primary therapy before medication and epicardial ablation.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
As many as 25% of patients taking statins may experience side effects. How should clinicians respond to the broad spectrum of side effects and variable severities reported? Host Dr. Alan Brown welcomes Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology at Duke University School of Medicine, to discuss statin intolerance and the most effective methods for counseling patients who experience this issue. Dr. Guyton's team has developed approaches that help many patients who have trouble taking statin drugs find alternative ways to lower their low-density lipoprotein (LDL) levels. Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and is known for his earlier work on lipid deposition in the arterial wall.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Debra Friedrich, DNP, ARNP, FNP-C, CLS
Join host Dr. Alan Brown and guest Dr. Debra Friedrich on the most common endocrine disorder in women- Polycystic Ovarian Syndrome (PCOS). They will review the epidemiology, prevalance, diagnosis, long-term risks and treatment options.
Dr. Debra Friedrich, DNP, ARNP, is an Assistant Professor at the University of South Florida College of Nursing and Director of the Family Nurse Practitioner Concentration. She is a family nurse practitioner and Clinical Lipid Specialist in practice in Bradenton, Florida.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Spencer Kroll, MD, PhD
The Food and Drug Administration has warned that patients taking cholesterol-fighting statins face a small increase in the risk of higher blood-sugar levels and of being diagnosed with diabetes. There has been conflicting information from several large trials about the effects of statin therapy on the development of diabetes and glycemic control.
Join host Dr. Alan Brown and Dr. Spencer Kroll, diplomate of the American Board of Clinical Lipidology and a board certified Internist. He also serves on the board of directors of the Northeast Lipid Association and runs The Cholesterol Treatment Center, a lipid clinic in Marlboro, New Jersey.
Host: Janet Wright, MD
Guest: Jeffrey Anderson, MD
Vitamin D insufficiency and deficiency are common because of a number of factors, not the least of which is a lack of exposure to sunlight. What role does vitamin D play in ensuring cardiovascular health, and should clinicians routinely test patients for such deficiency? Dr. Jeffrey Anderson, vice-chair of research in the department of medicine and associate chief of cardiology and director of cardiovascular research at Intermountain Medical Center, discusses current evidence about vitamin D and the heart, but says more prospective studies are needed to determine whether vitamin D plays an associated or causal role related to cardiovascular health. Is routine vitamin D supplementation useful for protecting cardiovascular health, or should clinicians wait for more evidence? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Thiruvinva Dharmarajan, MD FACP AGSF
Host: Eric Tangalos, MD
Patients in hospital settings are often screened and promptly treated for venous thromboembolism, or VTE, but perhaps less commonly in long-term care, even though these patients may be at risk. Dr. T.S. Dharmarajan, clinical director of the division of geriatrics at Montefiore Medical Center (North Division) in the Bronx, New York, discusses the medical conditions in long-term care that put patients at risk for VTE, and ways to assess patients for the condition. What anticoagulation medications and treatments may be used for treating VTE in long-term care? Should long-term care clinicians treat VTE as aggressively as hospitals often do, or are there other unique considerations clinicians should keep in mind for managing patients at risk for VTE in long-term care? Dr. Eric Tangalos hosts.
Guest: Thomas C. Wozniak, MD
Host: Aaron Carroll, MD
Currently, 3 to 5 million people per year suffer from heart failure in the United States; one-third of these patients suffer from Class III or Class IV heart disease. Host Dr. Aaron Carroll welcomes Dr. Thomas Wozniak, surgical director of the Indiana University Health Thoracic Transplant Program. Dr. Thomas discusses the advanced heart failure patient, and who is a candidate for ventricular assist device (VAD) therapy and cardiac transplantation and considerations about timing.
Host: Janet Wright, MD
Guest: Caldwell Esselstyn, Jr., MD
Some evidence suggests it is possible to prevent and reverse heart disease by adhering to a plant-based diet, but lifestyle changes are often the most challenging for physicians to prescribe and for patients to adopt. What strategies can physicians use to encourage a plant-based diet for patients who have or are at risk for having heart disease? Dr. Caldwell Esselstyn, director of the cardiovascular prevention and reversal program at the Cleveland Clinic Wellness Institute in Lyndhurst, Ohio and author of the book, Prevent and Reverse Heart Disease, surveys the worst culprits of the Western diet responsible for causing heart disease, and describes the crucial role that nitric oxide released from the endothelium plays in protecting blood vessels. Dr. Esselstyn shares his tips and strategies for promoting and, most importantly, following a plant-based diet, in the midst of a culture riddled with nutritionally-questionable foods. Join us for part 2 of our two-part interview with Dr. Esselstyn. Dr. Janet Wright hosts.
If you missed Part 1, listen now >>
Produced in Cooperation with
Host: Janet Wright, MD
Guest: David Kaplan, PhD
Although most bypass grafts are sourced from other parts of a patient's body, bioengineers are examining new materials that might be used for bypass grafts to reduce the risk of second-site complications. Silk has been a standard material in sutures for decades, and is now showing promise as a biomaterial in bypass grafts. Might silkworms help repair clogged arteries? Dr. David Kaplan, endowed chair, the Stern Family Professor of Engineering, and professor & chair of the department of biomedical engineering at Tufts University, discusses the advantages of silk protein as a biomaterial and related applications to cardiology. When might this new technology be applied from the bench to the bedside? Dr. Janet Wright hosts.
Produced in Cooperation with
Host: Janet Wright, MD
Guest: Robert Harrington, MD
Recent studies have raised doubts about the efficacy of some common treatments for cardiovascular disease, including: the use of PFO closures (based on the CLOSURE trial); some methods of cardiac resynchronization therapy (or CRT, based on the SMART-AV trial); telemonitoring for patients with congestive heart failure (based on the Tele-HF trial); and doubling the dose of clopidogrel in patients who had a poor response to the drug after percutaneous coronary intervention (based on the GRAVITAS trial). Dr. Robert Harrington, director of the Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina, reviews the evidence in each of these trials, and gauges the clinical impact of their findings. Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Richard Lange, MD, MBA
Host: Janet Wright, MD
First generation drug-eluting stents offer many advantages over bare metal stents, the most significant of which is their efficacy in reducing the rate of restenosis. Now second generation drug-eluting stents are proving to be even more beneficial. How are these second generation drug-eluting stents further reducing the risk of late stent thrombosis, myocardial infarction and repeat revascularization? Dr. Richard Lange, professor and executive vice chairman of medicine at the University of Texas Health Science Center, in San Antonio, Texas, discusses the structural and molecular differences between first and second generation drug-eluting stents. With all the advantages of the newer stents, however, there is also an increased cost. Are second generation drug-eluting stents enough of an improvement upon their first generation counterparts to warrant the higher cost? Dr. Janet Wright hosts.
Guest: Tatjana Rundek, MD, PhD
Host: Maurice Pickard, MD
Hundreds of millions of people may have insulin resistance worldwide. What is the connection between insulin resistance and the risk of ischemic stroke? Dr. Tatjana Rundek, associate professor of neurology and director of the clinical translational research division in the department of neurology of the Miller School of Medicine at the University of Miami, Florida, discusses her research on the risk of developing ischemic stroke among non-diabetic patients with insulin resistance with host Dr. Maurice Pickard. How can lipid-lowering medications help reduce the risk of stroke for non-diabetic patients with insulin resistance, and are any other medications on the horizon for these patients?
Host: Janet Wright, MD
Guest: Stuart Connolly, MD
Because atrial fibrillation increases the risk for stroke, especially among those with other underlying conditions, what anticoagulation therapies should be considered for these patients? Dr. Stuart Connolly, professor of medicine and director of the division of cardiology and the Salim Yusuf Chair in Cardiology at McMaster University in Ontario, Canada, weighs the benefits and risks of different anticoagulation therapies, in the context of the recent Randomized Evaluation of Long-Term Anticoagulation Therapy (or, RE-LY) trial. In addition to the standard warfarin and aspirin anticoagulants, there are now two promising new classes of anticoagulation therapy. How effective is dabigatran, compared to warfarin? What questions do we still need answered about anticoatulantion therapies that will be addressed in the years to come? Hosted by Dr. Janet Wright.
Produced in Cooperation with
Guest: David Kendall, MD
Host: Steven Edelman, MD
The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illuminate this quandary? Join host Dr. Steven Edelman and his guest, chief scientific and medical officer of the American Diabetes Association, Dr. David Kendall, as they discuss the effect of glycemic control on macrovascular outcomes in patients with diabetes.
Host: Janet Wright, MD
Guest: Albert Starr, MD
On the 50th anniversary of the first successful prosthetic mitral valve replacement, how far has cardiac surgery come, and where are we headed? Tune in to hear Dr. Albert Starr, co-founder of the first artificial mitral valve, medical director of the Providence Heart and Vascular Institute, and director of Academic Affairs & Bioscience Development for Providence Health & Services in Portland, Oregon, recounts his first foray into the field of valvular disease and the extraordinary process of inventing the first artificial mitral valve. What complications did Dr. Starr encounter during the design process, and what breakthrough allowed for success in long-term artificial valve replacement? He also discusses the development of what was perhaps one of the first ventures into outcomes research, with the creation of a system for long-term follow up of patients receiving valve replacement. What does Dr. Starr see as the "next big thing" in cardiac surgery? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Laurie Jacobs, MD
Host: Eric Tangalos, MD
Patients who have recently had orthopedic and other types of general surgery, those who have recently had a stroke, and those with an ongoing medical condition (such as heart disease) are at most risk for developing venous thromboembolic disease. Do most long-term care facilities screen for this condition among these patient populations, and when should physicians initiate prophylactic care? Dr. Laurie Jacobs, professor of clinical medicine and vice chairman of clinical and educational programs in the department of medicine at Albert Einstein College of Medicine and Montefiore Medical Center, and director of the Resnick Gerontology Center at Albert Einstein College of Medicine in Bronx, New York, discusses ways to reduce the risk of developing venous thromboembolism among long-term care patients. What is on the horizon in terms of new therapies? Hosted by Dr. Eric Tangalos.
Guest: Scott Levin, MD
Host: Lee Freedman, MD
Trauma patients with injury to one or more limb often have additional systemic injuries that need to be considered during treatment. One approach to limb salvage is the ortho-plastic technique, which involves integrated soft tissue and bone. This conversation covers some of the latest advances in limb salvage techniques that might benefit trauma patients, as well as those with diabetes or peripheral vascular disease. Dr. Scott Levin, professor and chair of orthopaedic surgery and professor of plastic surgery at Penn Medicine, discusses strategies for avoiding amputation. Dr. Lee Freedman hosts.
Produced in Cooperation with
Host: Alfred Bove, MD
Guest: Jeffrey Olin, DO
Fibromuscular dysplasia, most commonly found in the renal or carotid arteries, often goes undiagnosed, even though the condition may affect three- to five-percent of the U.S. patient population. What are symptoms of FMD, and in what patients should physicians screen for FMD, despite the absence of symptom presentation? Dr. Jeffrey Olin, professor of cardiology and director of vascular medicine at Mount Sinai in New York City, offers his insights on FMD, as Dr. Olin has dedicated much of his professional career to spreading awareness about the condition. Dr. Alfred Bove hosts.
Host: Steven Edelman, MD
Guest: Irwin Goldstein, MD
The vascular, neurologic, hormonal and psychological issues associated with the diabetes and metabolic syndromes are commonly the cause of sexual problems. What benefit does a multidisciplinary approach to sexual medical issues bring to people living with diabetes? Join host Dr. Steven Edelman and his guest, director of San Diego Sexual Medicine at Alvarado Hospital in Southern California, Dr. Irwin Goldstein, as they discuss both male and female sexual dysfunction, treatments and a multidisciplinary approach to sexual medical issues.
Host: Anthony Alessi, MD
Guest: Ralph Sacco, MD
Dr. Ralph Sacco, neurologist-in-chief at Jackson Memorial Hospital and the Miller Professor of Neurology, Epidemiology and Human Genetics at the Univeristy of Miami, joins host Dr. Anthony Alessi to discuss the FDA-approved treatment approaches for acute ischemic stroke, and what proportion of stokes each year are now treated with IV rTPA. Additionally, Dr. Sacco reviews the newly designated primary stroke centers throughout the United States, and how these have helped expand the treatement of stroke and organized healthcare professionals to provide the right treatment program for their patients in hospitals.
Host: Janet Wright, MD
Guest: John Alexander, MD, MHS
One of the reported benefits of endoscopic vein harvesting is a lower risk of wound complications following coronary bypass grafting, though it has yet to be established that long-term clinical outcomes for this technique are superior to those achieved using open harvesting under direct vision. New findings suggest a need to weigh short-term benefits against long-term outcomes. Host Dr. Janet Wright talks with Dr. John Alexander, associate professor of medicine at Duke University School of Medicine and senior author of these findings, which have been published in the New England Journal of Medicine. How can the surgeon, cardiologist and patient work together to determine the best course of treatment for each individual undergoing coronary bypass surgery?
Guest: Niren Angle, MD
Host: Steven Edelman, MD
People with diabetes are at increasingly higher risk for developing peripheral arterial disease. However, the disease may have no symptoms and often goes undiagnosed. What is the link between PAD and diabetes? Our guest, Dr. Niren Angle, chief of vascular and endovascular surgery at the University of California, San Diego, outlines the symptoms, diagnosis and treatment for peripheral artery disease. Join host Dr. Steven Edelman to learn more.
Guest: John Whapham, MD, MS
Host: Mark Nolan Hill, MD
Somewhere in between the fields of neurology and neurosurgery, we find physicians using less invasive techniques to perform procedures that could be classified as endovascular neurosurgery, or interventional neuroradiology, or more plainly, as neurology practiced through catheters. Dr. John Whapham, a neurointerventionalist and an assistant professor in the departments of neurology and neurological surgery at the Loyola University Chicago Stritch School of Medicine, explains how this area of practice has evolved in recent years, and previews what's in store for the future of this discipline, blending expertise across multiple specialties. Dr. Mark Nolan Hill hosts.
Guest: Evelyn Hermes-DeSantis, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
Pregnancy in patients with pulmonary arterial hypertension (PAH) is linked to several risks. Women of childbearing age are often encouraged to avoid pregnancy. But when pregnancy does occur, how can clinicians balance improvement of outcomes with considerations for the maternal and fetal health? Joining Dr. Charles Turck to discuss these issues and more is Dr. Evelyn Hermes-DeSantis, director of the Drug Information Service at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, and clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey.
Guest: Alan Moody, MBBS
Host: Larry Kaskel, MD
Can three-dimensional MRI help us measure potential risks for stroke associated with an intraplaque hemorrhage? We are rapidly learning more about the significance of intraplaque hemorrhage, and its role in cardiac and cerebrovascular disease. A better look at potential trouble spots could allow for earlier detection of an impending event, even in relatively asymptomatic individuals. Dr. Alan Moody, professor in the department of medical imaging at the University of Toronto Faculty of Medicine, shares his perspective on 3D MRI as an important tool to lead us in this direction. On a related note, Dr. Moody also provides some insight on what we can do patients with an intraplaque hemorrhage who is already on a statin, aspirin or another therapy to reduce their risk of having this happen again. Dr. Larry Kaskel hosts.
Guest: Bernard Cohen, MD
Host: Michael Greenberg, MD
Hemangiomas are common in infants, and often appear within the first few weeks of life. Although many infant hemangiomas are unsightly but regress after a few months, others can be large and disfiguring. Until recently, there have been no ideal treatment options, but there has been recent success using propranolol to treat infant hemangiomas. Host Dr. Michael Greenberg explores this exciting new treatment with Dr. Buddy Cohen, professor of dermatology and pediatrics at Johns Hopkins University School of Medicine.
Guest: Ralph Sacco, MD
Host: Shira Johnson, MD
Over 700,000 Americans have a new or recurrent stroke each year. Dr Ralph Sacco, professor and chairman of neurology at the University of Miami's Miller School of Medicine, discusses the leading research on treatment in the 'golden hour' after a stroke occurs. He reviews why thrombolytics have led the way after a dry infarct, but why your patients may need additional care only available in a comprehensive stroke center. As chief of neurology at Jackson Memorial Hospital in Miami and a leading researcher, Dr. Sacco joins host Dr Shira Johnson to talk about the state of the art in care after a CVA.
Guest: Michael Bresler
Host: Shira Johnson, MD
There are many vasoactive medications available to treat hypertension in an acute setting. Join Dr. Michael Bresler, professor in the division of emergency medicine at Stanford University School of Medicine and director of Emergency Medicine at the Mills-Peninsula Health System, to discuss the potent arsenal of acute care medications at your disposal. Dr. Shira Johnson is the host for this informative session on the use and misuse of vasodilators.
Guest: Michael Bresler
Host: Shira Johnson, MD
Do you know how to respond in your office to an unexpectedly elevated blood pressure in a patient not previously diagnosed with hypertension? Dr. Michael Bresler, professor in the division of emergency medicine at Stanford University School of Medicine and director of emergency medicine at the Mills-Peninsula Health System, discusses management of a new diagnosis of hypertension. Dr. Shira Johnson is the host as Dr. Bresler reviews a disease that affects over 60% of adults in the United States.
Host: Anthony Alessi, MD
Guest: Stephen Silberstein, MD
While the prevalence of migraine amongst Americans has remained fairly constant over the last fifteen years, our knowledge of migraine and the treatment options have grown significantly. What have we learned most recently about migraine and about vascular risks associated with migraine? Dr. Stephen Silberstein, professor of neurology and director of the Jefferson Headache Center at Thomas Jefferson University, joins host Dr. Anthony Alessi to discuss the latest research on treating migraine and the vascular risks associated with migraine.
Host: Doug Weaver, MD
Guest: Martin Leon, MD
Will drug-eluting stents prove safer and more effective without a metal structure? For all their merits, current stent technologies still present a series of drawbacks, including the severe complication of late thrombosis. Biodegradable polymers may hold the key to minimizing this and other concerns. Host Dr. Doug Weaver discusses the most promising areas of research in this area with Dr. Martin Leon, professor of medicine and associate director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York City.
Host: Doug Weaver, MD
Guest: Peter Berger, MD
It is no longer a question of whether antiplatelet therapy should be used following implantation of a drug-eluting stent, but rather to what extent and to what duration. With this in mind, many new challenges arise, from bleeding risks to drug intolerance and product cost. Host Dr. Doug Weaver welcomes Dr. Peter Berger, associate chief research officer and director of the Center for Clinical Studies at the Geisinger Clinic in central Pennsylvania, to discuss how we’re moving to address these concerns. Dr. Berger also details a series of related procedural circumstances—dental surgery, bronchoscopy, certain orthopaedic procedures and more—in which antiplatelet therapy need not be discontinued.
Guest: Wayne Peters, MD
Host: Larry Kaskel, MD
Recent studies indicate that some patients may not obtain the full benefits of aspirin's antiplatelet effects Guest Dr. Wayne Peters discusses with host Dr. Larry Kaskel the benefits of aspirin to prevent and manage heart disease, and the tests available to measure aspirin resistance or platelet function. Dr. Peters outlines the clinical importance of these tests and the various factors that can affect absorption including medications such as ibuprofen, smoking and high cholesterol. Tune in to hear how a simple urinary test will provide the primary care physician the information to effectively use aspirin for the prevention and management heart disease in combination with other prevention mechanisms.
Guest: Jill Jesurum, PhD
Host: Janet Wright, MD
Who would expect that a hole in the heart and a pain in the head are related? If you take care of patients who suffer from migraine headaches, host Dr. Janet Wright's interview with Dr. Jill Jesurum, scientific director of the Heart & Vascular Institute at Swedish Medical Center in Seattle, may shed light on some unanticipated benefits of treatment for migraineurs. Dr. Jesurum explains how patent foramen ovale (PFO) closure may impact the symptoms experienced by a migraine sufferer, and shares her perspective on which populations may benefit most from a PFO procedure.
Guest: Kate Phillips, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
Warfarin is one member of the anticoagulant class that presents a challenge to clinicians. Low-molecular weight heparins can be equally tricky, especially when it comes to dosing decisions in the obese, the renally compromised, and in patients with evolving pharmacokinetic profiles. How can we tailor our clinical approach to specific subtypes of patients who require anticoagulant therapy? Dr. Kate Phillips, clinical specialist in cardiology and anticoagulation at the Boston Medical Center, details special considerations for our approach to care. Dr. Charles Turck hosts.
Guest: Kate Phillips, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
Several factors impact our ability to safely and effectively prescribe warfarin and other anticoagulants. These issues include genetics, weight, renal impairment, and the potential for heparin-induced thrombocytopenia. How can we continue to improve our recognition of these factors that affect our patients' capacity to metabolize anticoagulants? Dr. Kate Phillips, clinical specialist in cardiology and anticoagulation at the Boston Medical Center, speaks with host Dr. Charles Turck about the challenges of anticoagulant therapy dosing, as well as the variation in response to therapy, based on ethnicity and other factors.
Host: Jennifer Shu, MD, FAAP
Guest: E. Steve Roach, MD
Pediatric and adolescent stroke differ from adult stroke in frequency, presentation, management and prognosis. What causes childhood stroke, and how can we diagnose and treat the condition? Dr. E. Steve Roach, professor of pediatrics and neurology at the Ohio State University College of Medicine, and chief of the division of child neurology at Nationwide Children's Hospital in Columbus, Ohio, explains who, among our young patients, is at greater risk for stroke and how the clinical presentation is often very similar to that of an elderly stroke victim. Looking at the long-term ramifications, how do our young stroke patients fare as they get older? Dr. Jennifer Shu hosts.
Guest: E. Steve Roach, MD
Host: Jennifer Shu, MD, FAAP
Stroke has been increasingly recognized among children in recent years. Stroke in neonates, in particular, occurs at a much higher rate than in older children. What are the leading risk factors for neonatal stroke? How does it present and how is it diagnosed? Host Dr. Jennifer Shu learns more about the evidence for managing stroke in newborns, as well as the likely short-term and long-term outcomes, from Dr. E. Steve Roach, professor of pediatrics and neurology at the Ohio State University College of Medicine, and chief of the division of child neurology at Nationwide Children's Hospital in Columbus, Ohio.
Guest: Ted Love, MD
Host: Bruce Japsen
Anticoagulants like heparin have been around for decades, but the drugs have drawbacks for many patients. Dr. Ted Love, Chief Executive of biotech company Nuvelo, tells host Bruce Japsen about targeted anticoagulant therapies that are being developed to be safer and more effective than the old standby heparin therapy and other blood treatments.
Guest: Ted Love, MD
Host: Bruce Japsen
With ongoing questions about the manufacturing of heparin in China and concerns about a potential shortage of the anticoagulant, some are wondering whether there is a need for new heparin alternatives. Dr. Ted Love, chief executive officer of the San Francisco biotech company Nuvelo, tells host Bruce Japsen about the biotech industry's pursuit of synthetic variations of the popular blood thinner.
Guest: Steven Greenberg, MD, PhD
Host: Maurice Pickard, MD
Dr. Steven Greenberg, associate professor of neurology at Harvard Medical School and director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital in Boston, talks with host Dr. Maurice Pickard about the somewhat unexpected finding of an increased frequency of cerebral microbleeds, and explains the potential impact of this discovery on cases of uncontrolled hypertension and cognitive changes. How might this complicate decisions to use antithrombotic therapy? Does this research add a new dimension to certain unexplained phenomena, such as lacunar infarcts or cerebral atrophy?
Guest: Beverly Green, MD, MPH
Host: Mark Nolan Hill, MD
The Internet plays such an integral role in so many of our lives, it's only natural to consider expanding its position in medicine. This process is underway, and moving rapidly in some areas, with the first large-scale, randomized clinical trial probing web-based hypertension interventions. How can we, as clinicians, adapt to new digital mechanisms for providing care? Does this particular hypertension concept mesh with the idea of a fee-for-service payment plan? Dr. Beverly Green, an affiliate investigator at the Group Health Center for Health Studies in Seattle, and the lead author of research published in JAMA on innovative web-based interventions for patients with uncontrolled hypertension, explains more about this collaborative approach to care with host Dr. Mark Nolan Hill.
Guest: Beverly Green, MD, MPH
Host: Mark Nolan Hill, MD
For each 10 millimeter drop toward normal systolic blood pressure, research tells us that heart disease mortality risk drops by an average of 30 percent. New internet-based hypertension interventions are proving they could produce this steep, impressive decline. How can these web initiatives help our patients take a more active role in their care? If patients are based at home, how can we ensure that they are following proper protocol for taking blood pressure measurements? Host Dr. Mark Nolan Hill takes a closer look at these issues and more with Dr. Beverly Green, an affiliate investigator at the Group Health Center for Health Studies in Seattle, and the lead author of research published in JAMA on innovative web-based interventions for patients with uncontrolled hypertension.
Guest: Jane Newburger, MD MPH
Host: Bill Rutenberg, MD
It's the leading cause of acquired heart disease in children. But pediatricians often face an arduous challenge when trying to confirm a diagnosis of Kawasaki disease. Dr. Jane Newburger, professor of pediatrics at Harvard Medical School and a nationally recognized expert in Kawasaki disease, discusses current clinical criteria for the disease and the protocol for diagnosing borderline cases with host Dr. Bill Rutenberg. Dr. Newburger also outlines the most effective treatment options for Kawasaki disease.
Guest: Sarah Tomasello, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How can we optimize erythropoetic therapy in patients with anemia of chronic kidney disease? How widespread is the problem of hyporesponsiveness to erythropoetic-stimulating agents? Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey, joins host Dr. Charles Turck.
Guest: Sarah Tomasello, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How are erythropoietic-stimulating agents (ESA) most helpful for patients with chronic kidney disease? What target levels of iron should clinicians maintain before starting ESA therapy, and what challenges will we encounter in this process? Host Dr. Charles Turck probes these questions and more with Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey.
Host: Lee Freedman, MD
Guest: Emile Mohler III, MD
How should we approach vulnerable plaques in the coronaries and how can we calculate more precise risk levels in both high- and average-risk patients? Host Dr. Lee Freedman addresses diagnosis and treatment options with Dr. Emile Mohler III, associate professor of medicine and director of vascular medicine within the University of Pennsylvania Health System.
Dr. Mohler passed away in October 2017. This interview honors his commitment and dedication to medicine.
Host: Lee Freedman, MD
Guest: Emile Mohler III, MD
A ruptured vascular plaque with subsequent thrombus often triggers the heart attack that occurs without warning. How do we identify and treat at-risk cardiac patients? Host Dr. Lee Freedman discusses an array of tools to evaluate plaque burden and promote plaque stabilization with Dr. Emile Mohler III, associate professor of medicine and director of vascular medicine within the University of Pennsylvania Health System.
Dr. Mohler passed away in October 2017. This interview honors his commitment and dedication to medicine.
Guest: Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP
Host: Charles Turck, PharmD, BCPS, BCCCP
Dr. Charles Turck is joined by guest Dr. Ann Wittkowsky, director of anticoagulation services at the University of Washington Medical Center and co-author of "Genetic Testing for Warfarin Dosing: Not Yet Ready for Primetime" appearing in the Journal Pharmacotherapy. Dr. Wittkowsky overviews some clinical pearls associated with anticoagulation therapy, and the challenges clinicians face delivering this care.
Guest: Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP
Host: Charles Turck, PharmD, BCPS, BCCCP
There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Guest: Suzanne Cannegieter, MD
Host: Gary Kohn, MD
Dr. Suzanne Cannegieter, Director of Clinical Epidemiology at Leiden University in the Netherlands, discusses her team's work with the international Wright Project focusing on connections between air travel and venous thrombosis.
Guest: Suzanne Cannegieter, MD
Host: Gary Kohn, MD
Dr. Suzanne Cannegieter, director of clinical epidemiology, and the lead international researcher for the Wright Project, from Leiden University Medical Center in the Netherlands, talks about the history of research on deep venous thrombosis and extensive air travel.
Guest: Jeanette Reschke, RN
Host: Susan Dolan, RN, JD
An estimated one billion venipunctures are performed annually and they are commonly viewed as one of the most painful invasive procedures performed. It takes an average of 2.4 sticks in order to obtain successful catheter placement. Is there a better way? Join Registered Nurse Jenny Reschke discuss the Vein Viewer.
Guest: Abbas Chamsuddin, MD
Host: Cathleen Margolin, PhD
Dr. Abbas Chamsuddin of the Emory School of medicine discusses the latest techniques for treating varicose veins.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Host: Paul Raeburn
Guest: Tim Westmoreland, PhD
What's good about the Federal/State Medicaid program, and how could it be improved? Tim Westmoreland, a lawyer and health care expert at the Georgetown University Health Law Institute in DC, discusses the problem of getting more people covered.